Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-205 in FGFR3-altered cisplatin-ineligible metastatic or unresectable urothelial carcinoma
2019-000721-50Phase 2Completed
- Sponsor
- Incyte
- Start
- Nov 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pemigatinib, pembrolizumab, gemcitabine and carboplatin in transitional cell carcinoma (TCC) and bladder cancer (3 arms), sponsored by Incyte. Primary endpoint: Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on 2019-000721-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000721-50.